Eli Lilly and Company reports $24.4 billion revenue for quarter ended September 30, 2026, up 38.6%
Eli Lilly and Company reported revenue of $24.4 billion for the quarter ended September 30, 2026, an increase of 38.6% from the same quarter a year earlier ($17.6 billion).
For the same period it posted net income of $6.45 billion, up 15.5%, or $7.22 per diluted share (6.21 a year earlier).
That is a net margin of 26.4%.
On Sanad's AAOIFI Standard 21 screen, Eli Lilly and Company is currently compliant: interest-bearing debt is 3.7% of market capitalisation (limit 30%), and impure income is 0.2% of revenue (limit 5%).
Is Eli Lilly and Company halal?
See the full AAOIFI screening of Eli Lilly and Company
See the full AAOIFI screening of Eli Lilly and Company
Source: 10-Q filed with the U.S. Securities and Exchange Commission on October 29, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.